



## Product Information

Product ID D0005

CAS No. 1195768-06-9

Chemical Name

Synonym

Formula  $C_{23}H_{20}F_3N_5O_2S_2 \cdot CH_3SO_3H$

Formula Wt. 615.67

Melting Point


Purity  $\geq 98\%$

Solubility soluble in DMSO

Store Temp  $-20^\circ C$

Ship Temp Ambient

**Description** Dabrafenib is a reversible kinase inhibitor with anticancer chemotherapeutic activity. This compound is selective primarily for mutant (V600E) B-Raf, but has also inhibited tumor growth in cells expressing other B-Raf mutants (V600K, V600D) and WT B-Raf. Dabrafenib is partially active against c-Raf as well. Dabrafenib is an ATP-competitive inhibitor that has been approved for clinical use in the treatment of unresectable or metastatic melanomas; it is also being examined for treatment of brain metastases and other cancers. This compound has a very high oral bioavailability.



**Bulk quantities available upon request**

**Product ID Size**

D0005 5 mg

D0005 25 mg

D0005 100 mg

**References** Ballantyne AD, Garnock-Jones KP. Dabrafenib: First Global Approval. *Drugs*. 2013 Jul 24. [Epub ahead of print] PMID: 23881668.

Huang T, Karsy M, Zhuge J, et al. B-Raf and the inhibitors: from bench to bedside. *J Hematol Oncol*. 2013 Apr 25;6:30. PMID: 23617957.

Klinac D, Gray ES, Millward M, et al. Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. *Front Oncol*. 2013;3:54. PMID: 23515890.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2012 Jul 28;380(9839):358-65. PMID: 22735384.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.